CAPR Traders Position for FDA Decision as Hiring Clues Fuel Retail Speculation
CAPR rose more than 4% overnight as retail traders debated whether hiring listings signal launch preparations ahead of an FDA decision.
Moderna’s Dual US-Canada Vaccine Wins Put Respiratory Portfolio in Focus
Moderna’s US and Canadian vaccine authorizations sharpen the case for a broader respiratory franchise beyond COVID-19 products.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Gilead Shares a New Livdelzi Catalyst as Phase 3 PBC Data Move Toward Regulatory Talks
Positive Phase 3 IDEAL data for Livdelzi could give Gilead a regulatory catalyst and strengthen its non-HIV pipeline div…
Palatin Technologies Regains Buy Rating as Analysts Highlight Melanocortin Pipeline
H.C. Wainwright resumed coverage of Palatin with a buy rating, highlighting Vyleesi, MC4R expertise and prior business-d…
Edgewise Therapeutics Shares Jump on Takeover Interest Report: What Traders Should Watch
EWTX gained after a report of takeover interest, putting deal-premium speculation and catalyst-driven volatility at the …
Satellos Resets DMD Trial Endpoint After FDA Talks as Investors Weigh the Data
Satellos Bioscience changed its DMD trial endpoint after FDA discussions, while open-label MRI data showed a 3.7-point r…
Moonlake’s FDA Alignment Sets Up a Key BLA Catalyst for MLTX Investors
Moonlake reports no remaining FDA gaps, putting an expected November 29 BLA acceptance date at the center of the MLTX re…
J&J’s Rybrevant Approval Adds a New Oncology Catalyst for Investors
Johnson & Johnson’s accelerated FDA approval for Rybrevant strengthens its oncology pipeline and puts regulatory executi…
Xeris’ Recorlev Ambition Pulls Forward Revenue Case as XERS Nears Seven-Year Highs
Xeris’ earlier Recorlev sales ambition gives XERS a sharper growth narrative, but clinical milestones and execution risk…
Viatris Stock Gains 1.6% as Q3 Results Put $19.51 Breakout in Focus
Viatris shares rose 1.6% after Q3 results, putting the $19.51 breakout level and prior FDA approval in focus for traders…
ANI Pharmaceuticals’ $560 Million Egetis Deal Signals Renewed Rare-Disease M&A Momentum
ANI Pharmaceuticals’ reported $560 million Egetis acquisition would expand its rare-disease portfolio and underscore cro…